Pregnancy Continuation and Mechanical Circulatory Support in Severe Myopericarditis
For a 26-week pregnant woman with myopericarditis and LVEF 25%, pregnancy continuation is feasible with aggressive multidisciplinary management, and if mechanical circulatory support becomes necessary, VA-ECMO should be the first-line device, with consideration of Impella 5.5 for more prolonged support or left ventricular unloading.
Feasibility of Pregnancy Continuation
Pregnancy continuation at 26 weeks is reasonable but requires intensive monitoring and readiness for rapid intervention. The ESC guidelines emphasize that urgent delivery, irrespective of gestation, may need to be considered in women presenting or remaining in advanced heart failure with hemodynamic instability 1. However, at 26 weeks, you have reached a gestational age where neonatal survival is possible (though with significant morbidity risk), making the risk-benefit calculation favor attempting to prolong pregnancy if maternal hemodynamics can be stabilized.
Key Management Principles During Pregnancy:
- Joint cardiac and obstetric care is mandatory 1
- Transfer immediately to a facility with mechanical circulatory support capabilities, including intra-aortic balloon pump, ventricular assist devices, and transplant teams 1
- Medical therapy is severely limited: ACE inhibitors, ARBs, and aldosterone antagonists are contraindicated 1
- Use hydralazine and nitrates for afterload reduction instead of ACE inhibitors 1
- Beta-blockers (metoprolol, NOT atenolol) should be used if tolerated 1
- Diuretics only if pulmonary congestion is present (furosemide or hydrochlorothiazide) 1
- Dopamine and levosimendan can be used for inotropic support 1
Anticoagulation Considerations:
With LVEF 25%, anticoagulation should be strongly considered due to high risk of ventricular thrombi and peripheral embolism (including cerebral) that are frequent in severe cardiomyopathy during pregnancy 1. The procoagulant state of pregnancy amplifies this risk.
Mechanical Circulatory Support Device Selection
If the patient becomes dependent on inotropes despite optimal medical therapy, mechanical circulatory support must be initiated urgently.
Primary Device Choice: VA-ECMO
VA-ECMO is the most commonly used and most appropriate first-line mechanical circulatory support in pregnant patients with cardiogenic shock 2. The evidence supporting this includes:
- VA-ECMO is feasible and effective in pregnancy-associated diagnoses requiring mechanical circulatory support, with no difference in mortality compared to non-pregnant patients 3
- Recent case reports demonstrate successful use of VA-ECMO in acute myocarditis during pregnancy with complete biventricular recovery 4
- VA-ECMO provides biventricular support, which is critical since myopericarditis can affect both ventricles 4
- It can be rapidly deployed in emergency situations
Secondary Device Option: Impella 5.5 (Axillary Approach)
Impella 5.5 via axillary approach should be considered for:
- Prolonged support needs - One case demonstrated 66 days of support initiated during pregnancy 5
- Left ventricular unloading - Can be used in conjunction with VA-ECMO for LV decompression 4
- Bridge to recovery or transplantation - Particularly if recovery doesn't occur within expected timeframe 5
The axillary approach is preferred over femoral to allow patient mobility and reduce complications during prolonged support 5.
Intra-Aortic Balloon Pump (IABP)
IABP is mentioned as an option 1, but given the severity (LVEF 25%), it provides insufficient hemodynamic support compared to VA-ECMO or Impella. Reserve this for less severe cases or as adjunctive therapy.
Critical Decision Points
When to Initiate Mechanical Support:
- Dependence on inotropes despite optimal medical therapy 1
- Progressive hemodynamic deterioration
- Development of cardiogenic shock (cardiac index <2.2 L/min/m², hypotension, end-organ hypoperfusion)
- Refractory ventricular arrhythmias 4
When to Deliver:
- Immediate delivery if maternal hemodynamic instability persists despite mechanical support
- At 26 weeks, attempt to gain additional weeks if mother is stable on support
- Balance fetal viability improvements (each week matters at this gestation) against maternal risk
- If on VA-ECMO with stable hemodynamics, consider continuing pregnancy to 28-32 weeks for improved neonatal outcomes
Prognosis Considerations
A critical point: viral myocarditis/myopericarditis has potential for recovery 1. Unlike dilated cardiomyopathy, there is significant potential for LV function improvement over the first 6 months. This relatively high rate of spontaneous recovery (approximately 50% in peripartum cardiomyopathy) must factor into decisions about mechanical support duration and transplant listing 1.
Post-Delivery Management:
Once delivered and hemodynamically stable, standard heart failure therapy can be fully applied 1. This includes:
- ACE inhibitors (benazepril, captopril, or enalapril if breastfeeding) 1
- Full-dose beta-blockers
- Aldosterone antagonists
- Aggressive diuresis as needed
Common Pitfalls to Avoid:
- Delaying transfer to advanced center - Transfer immediately when LVEF is this low, before crisis occurs
- Using atenolol - Specifically contraindicated in pregnancy 1
- Inadequate anticoagulation - Don't underestimate thromboembolic risk with severe LV dysfunction
- Premature transplant listing - Remember the potential for recovery; mechanical support should be viewed as bridge to recovery first
- Infection control - Infectious complications are associated with increased mortality on mechanical support 3